New York securities industry targets profits of 90 billions USD! Goldman Sachs (GS.US) breaks quarterly records three times, Wall Street bonuses to hit all-time high
Profits of the New York securities industry are expected to surpass 90 billions USD, exceeding last year’s record of 65.1 billions USD, with bonuses potentially reaching all-time highs; underwriting income has increased by 68%, contributing 26.3 billions USD to state finances.
Zhitong Finance APP notes that New York's trading and investment banking firms are having a stellar year, with record-breaking profits expected for the entire industry. At the current pace, profits will exceed $90 billion, and bonuses are predicted to reach all-time highs.
According to a report by New York State Comptroller Thomas DiNapoli, this annual profit estimate—based on growth in the first half of 2026—will easily surpass last year’s record of $65.1 billion. His office measures profits generated by broker-dealer operations of New York Stock Exchange member firms.
DiNapoli stated that as long as no major economic upheavals occur, these substantial returns should lead to a record-setting round of bonuses for financial professionals across the industry in the new year, although he did not specify exact figures.
Driven by market volatility and renewed confidence in M&A activity, major Wall Street investment banks have reported record revenues across key business lines so far this year. For example, Goldman Sachs has set a new quarterly record for all banks’ equity trading revenues for three consecutive quarters.
Wall Street is on track for a record $90 billion in profits
According to DiNapoli's report, for New York's securities industry, the first half of this year marks the two strongest quarters on record, thanks to a 68% increase in underwriting revenue and a 16.4% rise in account supervision and advisory activity income.
This prosperous year for Wall Street is a major boon for New York City and its job market. In 2025, industry employment is expected to reach 207,400 people, with the comptroller’s office projecting an additional 5,300 jobs will be added this year.
This is also a significant windfall for state finances. Through corporate and personal income taxes, the securities industry contributed at least $26.3 billion to New York State’s FY2025-26 budget, an increase of nearly 29% year-on-year.
The comptroller’s office stated that risks related to global conflicts, inflation, and artificial intelligence are an “increasing concern” for the industry and for New York State.
The report pointed out: “Given the industry’s growing contributions to the tax bases of New York City and State, a downturn would pose increasing risks to public finances and the broader regional economy.”
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Updated: 2-ArriVent’s oral lung cancer therapy fails in late-stage clinical trial, shares plunge
In the first paragraph, stock information was added. Paragraphs 2 to 8 provide a detailed introduction to the disease and the clinical trial situation. Reuters, Oct. 6 - ArriVent BioPharma (AVBP.O) said on Tuesday that its oral therapy for treating rare lung cancer failed to meet its primary goal of delaying disease progression in a late-stage clinical trial, leading to its shares plunging by 63% in premarket trading. The therapy, firmonertinib, targets previously untreated advanced non-small cell lung cancer (NSCLC) patients who carry a gene mutation called the EGFR exon 20 insertion, which can promote cancer growth. This mutation accounts for about 0.5% to 1% of all NSCLC cases. NSCLC represents about 85% of all lung cancer cases. In the trial, according to independent reviewers, the 240mg dosage developed by ArriVent extended median progression-free survival to 11 months, compared to 9.5 months in the chemotherapy group. Chief Executive Officer Bing Yao stated that the improvement in progression-free survival (defined as the length of time patients live without worsening or spread of disease) was not significant. "These disappointing results are not what we had hoped for, especially for patients with EGFR exon 20 insertion-mutant NSCLC who are in urgent need of more effective treatments," said Yao. The company is evaluating the full data set to determine the most suitable development path for firmonertinib. ArriVent stated that no new safety signals were observed in the trial. The therapy has already been approved in China for non-small cell lung cancer patients carrying specific mutations. (For the convenience of non-English language speakers, Reuters has automated the translation of its reporting into several other languages. Due to possible errors or missing context in automated translation, Reuters does not guarantee the accuracy of automated translated texts and provides them for readers’ convenience only. Reuters accepts no responsibility for any damages or losses caused by the use of the automated translation feature.)
Sector Update: Consumer Stocks Edge Higher Premarket Tuesday
09:15 AM EDT, 10/06/2026 (MT Newswires) -- Consumer stocks were edging higher premarket Tuesday, with the State Street Consumer Staples Select Sector SPDR ETF (XLP) up 0.1% and the State Street Consumer Discretionary Select Sector SPDR ETF (XLY) advancing by 0.4%. Nomad Foods (NOMD) stock was up nearly 3% after the company said it now expects fiscal 2026 organic revenue to decline 2% to 3%, compared with its previous guidance for a decline of 2% to 5%. PepsiCo (PEP) and Monster Beverage (MNST) can continue to label their cans in India as energy drinks after a court ruling, Reuters reported, citing a lawyer present at the hearing. PepsiCo shares were slightly higher and Monster Beverage stock was down 0.3% pre-bell. B&G Foods (BGS) said it cancelled its agreement to sell Green Giant Canada to Nortera Foods on Monday, after failing to obtain Canadian regulatory approval. Shares of B&G Foods were up more than 1% premarket.
Update: TORM Shareholder Prices Secondary Offering of 6.3 Million Class A Shares
09:04 AM EDT, 10/06/2026 (MT Newswires) -- (Updates with pricing details in the headline and the first paragraph; and the offering close date in the last paragraph.) TORM (TRMD) said Tuesday that OCM Njord, a company indirectly owned by funds managed by Oaktree Capital Management and its affiliates, priced a secondary offering of 6.3 million class A shares for gross proceeds of about $253.5 million. The company said OCM Njord owns about 6% of its class A shares before the offering. TORM is not selling any shares and will not receive proceeds from the offering, the company said. The offering is expected to close on Wednesday, TORM said.
NexPoint Residential Trust schedules Q3 2026 earnings conference call
NexPoint Residential Trust schedules a third-quarter 2026 earnings conference call for Nov. 3, 2026 at 11:00 a.m. ET. Third-quarter 2026 results release set for before the market open on Nov. 3, 2026. Live webcast planned on https://nxrt.nexpoint.com; replay expected to remain available for 60 days. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NexPoint Residential Trust Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610060900PR_NEWS_USPR_____NY63815) on October 06, 2026, and is solely responsible for the information contained therein.
Crypto prices
More
